11th Apr 2011 16:31
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | ||||||||||||||||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | Allergy Therapeutics PLC | |||||||||||||||||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||||||||||||||||
An acquisition or disposal of voting rights | x | |||||||||||||||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||||||||||||||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||||||||||||||||
An event changing the breakdown of voting rights | ||||||||||||||||||
Other (please specify): | ||||||||||||||||||
3. Full name of person(s) subject to thenotification obligation: iii | Highclere International Investors LLP
| |||||||||||||||||
4. Full name of shareholder(s) (if different from 3.):iv | The Highclere International Investors International Smaller Companies Fund
The Highclere (Jersey) International Investors Smaller Companies Fund | |||||||||||||||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 8th April, 2011 | |||||||||||||||||
6. Date on which issuer notified: | 11th April, 2011 | |||||||||||||||||
7. Threshold(s) that is/are crossed orreached: vi, vii | Below 3% | |||||||||||||||||
8. Notified details: | ||||||||||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||||||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||||
Ordinary |
9,372,940 |
9,372,940 |
8,670,540 |
8,670,540
|
0 |
2.79% |
0 | |||||||||||
GB00B02LCQ05 | ||||||||||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||||
N/A | N/A | N/A | N/A | N/A | ||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |||||||||||||
N/A |
N/A |
N/A |
N/A |
N/A | Nominal | Delta | ||||||||||||
N/A | N/A | |||||||||||||||||
Total (A+B+C) | ||||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||||
8,670,540
| 2.79% | |||||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||||||||||||||||||
N/A | ||||||||||||||||||
Proxy Voting: | ||||||||||||||||||
10. Name of the proxy holder: |
Highclere International Investors LLP | |||||||||||||||||
11. Number of voting rights proxy holder will ceaseto hold: | Not Applicable | |||||||||||||||||
12. Date on which proxy holder will cease to holdvoting rights: | Not Applicable | |||||||||||||||||
13. Additional information: | Highclere International Investors LLP ("Highclere LLP") acts as investment manager for the clients detailed in Question 4 above (the "Clients"). In acting for the Clients, Highclere LLP is given full discretion over their investments and are empowered to vote on their behalf. However, Highclere LLP does not act as the Clients' custodian and therefore shares are not held in Highclere LLP's name but in the name of each Client's custodian bank.
| |||||||||||||||||
14. Contact name: | Fergus Gilmour, Compliance Officer | |||||||||||||||||
15. Contact telephone number: | 0207-258-9845 | |||||||||||||||||
Annex: Notification of major interests in share | ||||||||||||||||||
A: Identity of the persons or legal entity subject to the notification obligation | ||||||||||||||||||
Full name (including legal form of legal entities)
|
Highclere International Investors LLP | |||||||||||||||||
Contact address (registered office for legal entities)
| 2 Manchester Square London W1U 3PA | |||||||||||||||||
Phone number & email
| 0207-258-9845 | |||||||||||||||||
Other useful information (at least legal representative for legal persons)
| Attn: Fergus Gilmour, Compliance Officer | |||||||||||||||||
B: Identity of the notifier, if applicable | ||||||||||||||||||
Full name
| Highclere International Investors LLP
| |||||||||||||||||
Contact address
| 2 Manchester Square London W1U 3PA | |||||||||||||||||
Phone number & email
| 0207-258-9845 | |||||||||||||||||
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) | Attn: Fergus Gilmour, Compliance Officer | |||||||||||||||||
C: Additional information | ||||||||||||||||||
Highclere International Investors LLP ("Highclere LLP") acts as investment manager for the clients detailed in Question 4 above (the "Clients"). In acting for the Clients, Highclere LLP is given full discretion over their investments and are empowered to vote on their behalf. However, Highclere LLP does not act as the Clients' custodian and therefore shares are not held in Highclere LLP's name but in the name of each Client's custodian bank.
| ||||||||||||||||||
Related Shares:
Allergy Thera.